Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Lee

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal for Immunotherapy of Cancer|March 22, 2024
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cellsMaxim Yankelevich, Archana Thakur, Shakeel Modak, et al.
Transplantation and Cellular Therapy|May 14, 2026
Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Leslie Crofford, Andrew P Jallouk, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Blood|December 18, 2012
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaWaleed Haso, Daniel W Lee, Nirali N Shah, et al.
Blood Advances|December 17, 2021
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapyElizabeth M Holland, Bonnie Yates, Alex Ling, et al.
Haematologica|February 9, 2018
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphomaHaneen Shalabi, Ira L Kraft, Hao-Wei Wang, et al.
Neuro-Oncology|February 11, 2022
Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignanciesHaneen Shalabi, Staci Martin, Bonnie Yates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALLNirali N Shah, Daniel W Lee, Bonnie Yates, et al.
Blood Advances|October 7, 2021
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysLekha Mikkilineni, Bonnie Yates, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer|May 9, 2022
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulationElizabeth M Holland, John C Molina, Kniya Dede, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal for Immunotherapy of Cancer|March 22, 2024
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cellsMaxim Yankelevich, Archana Thakur, Shakeel Modak, et al.
Transplantation and Cellular Therapy|May 14, 2026
Chimeric Antigen Receptor T-Cell Therapy in Autoimmune Disorders: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Leslie Crofford, Andrew P Jallouk, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Blood|December 18, 2012
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaWaleed Haso, Daniel W Lee, Nirali N Shah, et al.
Blood Advances|December 17, 2021
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapyElizabeth M Holland, Bonnie Yates, Alex Ling, et al.
Haematologica|February 9, 2018
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphomaHaneen Shalabi, Ira L Kraft, Hao-Wei Wang, et al.
Neuro-Oncology|February 11, 2022
Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignanciesHaneen Shalabi, Staci Martin, Bonnie Yates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2021
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALLNirali N Shah, Daniel W Lee, Bonnie Yates, et al.
Blood Advances|October 7, 2021
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysLekha Mikkilineni, Bonnie Yates, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer|May 9, 2022
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulationElizabeth M Holland, John C Molina, Kniya Dede, et al.
Pageof 6